Is this FDA enforcement data for Hubei JXBio Pharmaceutical Co., Ltd. official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has Hubei JXBio Pharmaceutical Co., Ltd. had?

Argus HQ has recorded 1 FDA events for Hubei JXBio Pharmaceutical Co., Ltd.: 0 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against Hubei JXBio Pharmaceutical Co., Ltd.?

The most recent FDA event Argus HQ has on file for Hubei JXBio Pharmaceutical Co., Ltd. is dated 2025-03-14, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Hubei JXBio Pharmaceutical Co., Ltd. automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Hubei JXBio Pharmaceutical Co., Ltd. is observed, this page's event count and history update automatically.

Hubei JXBio Pharmaceutical Co., Ltd. — FDA Enforcement History

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	0
Approval records	0
Form 483 inspection citations	1
Most recent action	March 14, 2025

In short: Argus HQ has recorded 1 FDA events for Hubei JXBio Pharmaceutical Co., Ltd.: 0 warning letters, 0 recalls, 0 approvals, and 1 inspection 483 observations. These events span from 2025-03-14 to 2025-03-14. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Hubei JXBio Pharmaceutical Co., Ltd. has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2025-03-14, Argus HQ recorded an FDA Form 483 inspection citation for Hubei JXBio Pharmaceutical Co., Ltd., rated "high" severity in Argus HQ's classification: Hubei JXBio Pharmaceutical Co., Ltd. -- FDA 483: 1 observation (2025-03-14). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Frequently asked questions

Is this FDA enforcement data for Hubei JXBio Pharmaceutical Co., Ltd. official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has Hubei JXBio Pharmaceutical Co., Ltd. had?: Argus HQ has recorded 1 FDA events for Hubei JXBio Pharmaceutical Co., Ltd.: 0 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against Hubei JXBio Pharmaceutical Co., Ltd.?: The most recent FDA event Argus HQ has on file for Hubei JXBio Pharmaceutical Co., Ltd. is dated 2025-03-14, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for Hubei JXBio Pharmaceutical Co., Ltd. automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Hubei JXBio Pharmaceutical Co., Ltd. is observed, this page's event count and history update automatically.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Hubei JXBio Pharmaceutical Co., Ltd. -- FDA 483: 1 observation (2025-03-14) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). Hubei JXBio Pharmaceutical Co., Ltd. — FDA Enforcement History. Digital Empire LLC. Retrieved from https://argushq.ai/company/hubei-jxbio-pharmaceutical-co-ltd

MLA

"Hubei JXBio Pharmaceutical Co., Ltd. — FDA Enforcement History." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/company/hubei-jxbio-pharmaceutical-co-ltd.

Chicago

Argus HQ Research. "Hubei JXBio Pharmaceutical Co., Ltd. — FDA Enforcement History." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/hubei-jxbio-pharmaceutical-co-ltd.

BibTeX

@misc{argushq_argushq_ai_company_hubei_jxbio_pharmaceutical_co_ltd_2025,
  title = {Hubei JXBio Pharmaceutical Co., Ltd. — FDA Enforcement History},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/hubei-jxbio-pharmaceutical-co-ltd},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗